The biggest Biotech IPO in Hong Kong stock in 2025! Insili Intelligence (03696) opens a stock offering: it has the fastest growing AI drug in the world

The Zhitong Finance App learned that Insili Intelligence (03696), which holds the fastest progressing AI drug in the world, offered shares from December 18 to December 23. The IPO plans to issue 94,690,500 H shares, of which the Hong Kong public offering accounts for 10% and the international offering accounting for 90%. The sale price is HK$24.05 per share, 500 shares per lot, and the entry fee is HK$12146.27 for the first lot. The company is expected to be listed for sale on December 30. Judging from the amount of capital raised, it is expected to be the largest Biotech IPO in the Hong Kong stock market in 2025.

In this listing, Insili Intelligence introduced Eli Lilly, Tencent, Temasek, Schroder, UBS, Oak Capital, E-Fangda, Taikang Life, etc. as cornerstone investors. Fifteen top investment institutions subscribed a total of US$115 million, covering global pharmaceutical companies, leading international sovereign funds, large asset management companies, global theme funds, and leading domestic public equity and insurance.

It is worth noting that the cornerstone investors, Lilly and Tencent each represent the leading forces in the biomedicine and technology sectors — the two major industrial tracks where Innosilicon Intelligence is located. This is also the first time Eli Lilly has entered the cornerstone investors. At the same time, Cornerstone investors showed distinct international attributes. Not only do they have strong financial strength, but they are also known for “long-term holding and value growth”. Furthermore, before the IPO, Inosilicon Smart's investment lineup was already very large, including well-known institutions such as Huaping Capital, B Capital, Prosperity7, Eli Lilly Asia Fund, Baidu Venture Capital, Qiming Venture Capital, Sequoia China, and Yao Ming Kangde.

Through Pharma.ai, the self-developed generative artificial intelligence platform Pharma.ai, Insili Intelligence has generated more than 20 clinical or IND reporting assets. Three of these assets have been authorized to international pharmaceutical and healthcare companies, with a total contract value of US$2 billion, including a total advance payment of approximately US$110.0 million and milestone payments of approximately US$1.9 billion, and a Phase II asset in the self-development stage, which is in a relatively advanced stage in the industry.

Relying on the self-developed Pharma.ai platform, Insili Intelligence has efficiently built a pipeline portfolio covering more than 30 innovative projects, covering a wide range of fields such as oncology, immunity, fibrosis, and metabolism. According to R&D data disclosed by the company, it takes an average of no more than 18 months to develop an innovator from 0 to 1, which is far shorter than traditional methods (an average time of 4.5 years). The company's core asset, Rentosertib (ISM001-055), is also expected to become the world's first AI-enabled drug candidate to be discovered and entered phase III clinical trials.

In terms of commercialization, Insilicon Smart's business is all over the world. Of the 20 pharmaceutical companies with the highest revenue in the world, 13 have cooperated with Insilicon Smart on software platforms. In addition, Insili Intelligence has reached 3 pipeline licensing agreements with global pharmaceutical companies such as Exelixis and Menarini, bringing the company a potential revenue of 2 billion US dollars. At the same time, a number of world-renowned pharmaceutical companies, including Sanofi, Eli Lilly, Fosun Pharmaceuticals, etc., have reached drug research and development cooperation with Insili Intelligence.

With advanced AI technology and deep accumulation in pipeline development, Insili Intelligence may experience a double acceleration in the capital market and clinical implementation. After this successful listing, Insili Intelligence is expected to become the “first AI innovative drug stock” of the Hong Kong stock market, injecting key capital impetus into the AI pharmaceutical circuit.